Nkarta, Inc. plans to construct new manufacturing facility. The facility will be home for company’s headquarters including administrative offices and laboratories for research & development activities.
The facility covering an area of 88,000 square foot facility will be used for supporting research and development activities and manufacturing of Nkarta's cell therapy pipeline in future.
The new state-of-the-art manufacturing center is custom designed to compliment and optimise the production of several off-the-shelf NK cell therapy investigational products. Moreover, the center will also produce materials for potential clinical trials.
The facility is expected to provide cost-effective treatment and meet the commercial production of cell therapies which can be made easily available for the cancer patients.
Recently, the construction of 2,700 square foot cGMP facility was completed in California and the construction of this new facility is expected to begin its operation by the end of 2023.